{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T06:39:00Z","timestamp":1768286340541,"version":"3.49.0"},"reference-count":79,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2010,12,1]],"date-time":"2010-12-01T00:00:00Z","timestamp":1291161600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2010,12]]},"DOI":"10.1016\/j.leukres.2010.05.023","type":"journal-article","created":{"date-parts":[[2010,6,23]],"date-time":"2010-06-23T08:36:31Z","timestamp":1277282191000},"page":"1551-1555","source":"Crossref","is-referenced-by-count":41,"title":["The lower risk MDS patient at risk of rapid progression"],"prefix":"10.1016","volume":"34","author":[{"given":"Moshe","family":"Mittelman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Howard S.","family":"Oster","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Hoffman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Drorit","family":"Neumann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2010.05.023_bib1","series-title":"Hematology \u2013 basic principles and practice","first-page":"1195","article-title":"Myelodysplastic syndromes: biology and treatment","author":"De Angelo","year":"2005"},{"key":"10.1016\/j.leukres.2010.05.023_bib2","first-page":"468","article-title":"The myelodysplastic syndromes \u2013 1990","volume":"26","author":"Mittelman","year":"1990","journal-title":"Isr J Med Sci"},{"key":"10.1016\/j.leukres.2010.05.023_bib3","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1046\/j.1365-2141.2003.03907.x","article-title":"Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes","volume":"120","author":"Bowen","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1016\/j.leukres.2010.05.023_bib4","unstructured":"List AF, Pedersen-Bjergaard J, Garcia-Manero G. Myelodysplastic synsdromes. Hematology 2007 \u2013 Am Soc Hem Education Program Book, p. 392\u2013411."},{"key":"10.1016\/j.leukres.2010.05.023_bib5","doi-asserted-by":"crossref","unstructured":"Nimer SD, Hellstrom-Lindberg E, Cazzola M, Kroger N. Myelodysplastic syndromes. Hematology 2008 \u2013 Am Soc Hem Education Program Book, p. 43\u201367.","DOI":"10.1182\/asheducation-2008.1.42"},{"key":"10.1016\/j.leukres.2010.05.023_bib6","doi-asserted-by":"crossref","unstructured":"Steensma DP, Sekeres MA, Leitch HA, Vickars LM. Myelodysplastic syndromes. Hematology 2009 \u2013 Am Soc Hem Education Program Book, p. 645\u2013674.","DOI":"10.1182\/asheducation-2009.1.645"},{"key":"10.1016\/j.leukres.2010.05.023_bib7","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1056\/NEJMra0902908","article-title":"Myelodysplastic syndromes","volume":"361","author":"Tefferi","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2010.05.023_bib8","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1182\/blood.V89.6.2079","article-title":"International scoring system for evaluating prognosis in myelodysplastic syndromes","volume":"89","author":"Greenberg","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2010.05.023_bib9","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/j.1365-2141.1982.tb08475.x","article-title":"Proposals for the classification of the myelodysplastic syndromes","volume":"51","author":"Bennett","year":"1982","journal-title":"Br J Haematol"},{"key":"10.1016\/j.leukres.2010.05.023_bib10","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1182\/blood.V80.3.841.841","article-title":"Subcutaneous erythropoietin for treatment of refractory anemia in hematologic disorders","volume":"80","author":"Mittelman","year":"1992","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2010.05.023_bib11","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1046\/j.1365-2141.2003.04153.x","article-title":"A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin+granulocyte colony-stimulating factor: significant effects of on quality of life","volume":"120","author":"Hellstrom-Lindberg","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1016\/j.leukres.2010.05.023_bib12","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1046\/j.1365-2141.1997.4013211.x","article-title":"Erythroid response to treatment with G-CSF plus erythropoietin for the anemia of patients with myelodysplastic syndrome: proposal for a preditive model","volume":"99","author":"Hellstrom-Lindberg","year":"1997","journal-title":"Br J Haematol"},{"key":"10.1016\/j.leukres.2010.05.023_bib13","doi-asserted-by":"crossref","first-page":"3607","DOI":"10.1200\/JCO.2007.15.4906","article-title":"Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome","volume":"26","author":"Jadersten","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2010.05.023_bib14","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1200\/JCO.2009.24.7999","article-title":"Safety and efficacy of romiplostim in patients with low-risk myelodysplastic syndrome and thrombocytopenia","volume":"28","author":"Kantarjian","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2010.05.023_bib15","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1182\/blood.V98.4.958","article-title":"Thalidomide produces transfusion independence in log-standing refractory anemias of patients with myelodysplastic syndromes","volume":"98","author":"Raza","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2010.05.023_bib16","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJMoa061292","article-title":"Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion","volume":"355","author":"List","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2010.05.023_bib17","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1182\/blood-2007-01-068833","article-title":"Phase 2 study of lenalidomide in transfusion-dependent, low-risk and intermediate-1-risk myelodysplastic syndromes with karyotypes other than deletion 5q","volume":"111","author":"Raza","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2010.05.023_bib18","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V114.22.944.944","article-title":"RBC transfusion independence and safety profile of lenalidomide 5 or 10mg in pts with low- or Int-1-risk MDS with del 5q\u2212: results from a randomized phase III trial (MDS-004)","volume":"114","author":"Fenaux","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2010.05.023_bib19","doi-asserted-by":"crossref","first-page":"156","DOI":"10.7326\/0003-4819-137-3-200208060-00007","article-title":"Anti thymocyte globulin to treatment of the bone marrow failure associated with myelodysplastic syndromes","volume":"137","author":"Molldrem","year":"2002","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.leukres.2010.05.023_bib20","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1002\/ajh.21269","article-title":"Consensus statement on iron overload in myelodysplastic syndromes","volume":"83","author":"Bennett","year":"2008","journal-title":"Am J Hematol"},{"key":"10.1016\/j.leukres.2010.05.023_bib21","first-page":"374","article-title":"Iron chelation therapy in patients with myelodysplastic syndromes \u2013 consensus conference guidelines (For the MDS Israel Group and The Israel Society of Hematology)","volume":"10","author":"Mittelman","year":"2008","journal-title":"Isr Med Assoc J"},{"key":"10.1016\/j.leukres.2010.05.023_bib22","doi-asserted-by":"crossref","first-page":"6361","DOI":"10.1158\/0008-5472.CAN-06-0080","article-title":"Combined DNA methyl transferase and histone deacetylase inhibition in the treatment of myeloid neoplasms","volume":"66","author":"Gore","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.leukres.2010.05.023_bib23","doi-asserted-by":"crossref","first-page":"3895","DOI":"10.1200\/JCO.2005.05.4346","article-title":"Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8241, 8921, and 9221 by the Cancer and Leukemia Group B","volume":"24","author":"Silverman","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2010.05.023_bib24","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1470-2045(09)70003-8","article-title":"Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomized, open-label, phase III study","volume":"10","author":"Fenaux","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.leukres.2010.05.023_bib25","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1182\/blood.V98.8.2326","article-title":"Intensive chemotherapy followed by allogeneic or autologous stem cell transplantation for patients with myelodysplastic syndromes (MDSs) and acute myeloid leukemia following MDS","volume":"98","author":"de Witte","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2010.05.023_bib26","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1182\/blood-2002-02-0527","article-title":"Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome","volume":"100","author":"Deeg","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2010.05.023_bib27","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1038\/sj.leu.2403963","article-title":"Refinement of the International Prognostic Scoring system (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with primary myelodysplastic syndromes (MDS)","volume":"19","author":"Germing","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2010.05.023_bib28","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1002\/ajh.21249","article-title":"International MDS risk analysis workshop (IMRAW)\/IPSS reanalyzed: impact of cytopenias on clinical outcomes in myelodysplastic syndromes","volume":"83","author":"Kao","year":"2008","journal-title":"Am J Hematol"},{"key":"10.1016\/j.leukres.2010.05.023_bib29","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1002\/cncr.23697","article-title":"Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System","volume":"113","author":"Kantajian","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2010.05.023_bib30","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s12185-009-0403-5","article-title":"Prospective analysis of clinical and cytogenetic features of 435 cases of MDS diagnosed using the WHO (2001) classification: a prognostic scoring system for predicting survival in RCMD","volume":"90","author":"Wang","year":"2009","journal-title":"Int J Hematol"},{"key":"10.1016\/j.leukres.2010.05.023_bib31","doi-asserted-by":"crossref","first-page":"5358","DOI":"10.1200\/JCO.2006.07.5598","article-title":"Myelodysplastic syndromes in patients younger than age 50","volume":"24","author":"Kuendgen","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2010.05.023_bib32","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1093\/annonc\/mdp264","article-title":"Prognostic impact of age and gender in 897 untreated patients with primary myelodysplastic syndromes","volume":"21","author":"Nosslinger","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.leukres.2010.05.023_bib33","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1093\/annonc\/mdp258","article-title":"Comorbidity as prognostic variable in MDS: comparative evaluation of the HCT-Ci and CCI in a core dataset of 149 patients of the Austrian MDS Study Group","volume":"21","author":"Sperr","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.leukres.2010.05.023_bib34","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1056\/NEJMp048266","article-title":"Myelodysplastic syndromes \u2013 coping with ineffective hematopoiesis","volume":"352","author":"Cazzola","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2010.05.023_bib35","doi-asserted-by":"crossref","first-page":"7594","DOI":"10.1200\/JCO.2005.01.7038","article-title":"Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision-making","volume":"23","author":"Malcovati","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2010.05.023_bib36","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1200\/JCO.2006.08.5696","article-title":"Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes","volume":"25","author":"Malcovati","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2010.05.023_bib37","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1016\/j.leukres.2009.06.033","article-title":"Impact of transfusion dependency on survival in patients with early myelodysplastic syndrome without excess blasts","volume":"33","author":"Cermak","year":"2009","journal-title":"Leuk Res"},{"key":"10.1016\/j.leukres.2010.05.023_bib38","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/j.1365-2141.1984.tb06079.x","article-title":"Bone marrow histology in myelodysplastic syndromes. II. Prognostic value of abnormal localization of immature precursors in MDS","volume":"58","author":"Tricot","year":"1984","journal-title":"Br J Haematol"},{"key":"10.1016\/j.leukres.2010.05.023_bib39","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1200\/JCO.2008.18.2246","article-title":"Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndromes","volume":"27","author":"Della Porta","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2010.05.023_bib40","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1159\/000101709","article-title":"Histopathology in the diagnosis and classification of acute myeloid leukemia, myelodysplastic syndromes, and myelodysplastic\/myeloproliferative diseases","volume":"74","author":"Orazi","year":"2007","journal-title":"Pathobiology"},{"key":"10.1016\/j.leukres.2010.05.023_bib41","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.leukres.2004.08.008","article-title":"The presence of clonal cell subpopulations in peripheral blood and bone marrow of patients with refractory cytopenia with multilineage dysplasia but not in patients with refractory anemia may reflect a multistep pathogenesis of myelodysplasia","volume":"29","author":"Cermak","year":"2005","journal-title":"Leuk Res"},{"key":"10.1016\/j.leukres.2010.05.023_bib42","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.leukres.2007.08.006","article-title":"Hypocellularity in myelodysplastic syndrome is an independent factor which predicts a favorable outcome","volume":"32","author":"Yue","year":"2008","journal-title":"Leuk Res"},{"key":"10.1016\/j.leukres.2010.05.023_bib43","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1002\/ajh.2830430302","article-title":"High Ia (HLA-DR) and low CD11b (Mo1) expression may predict early conversion to leukemia in myelodysplastic syndromes","volume":"43","author":"Mittelman","year":"1993","journal-title":"Am J Hematol"},{"key":"10.1016\/j.leukres.2010.05.023_bib44","first-page":"205","article-title":"The prognostic value of maturation-associated phenotypic abnormalities in myelodysplastic syndromes","volume":"32","author":"Lorand-Metz","year":"2008","journal-title":"Leuk Res"},{"key":"10.1016\/j.leukres.2010.05.023_bib45","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1182\/blood-2007-07-098764","article-title":"Identification of distinct prognostic subgroups in low- and intermediate-1-risk myelodysplastic syndromes by flowcytometry","volume":"111","author":"van de Loosdrecht","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2010.05.023_bib46","doi-asserted-by":"crossref","first-page":"5202","DOI":"10.1002\/cncr.24575","article-title":"The heterogenous prognosis of patients with myelodysplastic syndrome and chromosome 5 abnormalities: how does it relate to the original lenalidomide experience in MDS?","volume":"115","author":"Kantarjian","year":"2009","journal-title":"Cancer"},{"issue":"September","key":"10.1016\/j.leukres.2010.05.023_bib47","article-title":"Chromosomal instability correlates with poor outcome in patients with myelodysplastic syndromes irrespectively of the cytogenetic risk group","author":"Helig","year":"2009","journal-title":"J Cell Mol Med"},{"key":"10.1016\/j.leukres.2010.05.023_bib48","first-page":"3557","article-title":"Telomere shortening associated with disease evolution patterns in myelodysplastic syndromes","volume":"54","author":"Ohyashiki","year":"1994","journal-title":"Cancer Res"},{"key":"10.1016\/j.leukres.2010.05.023_bib49","doi-asserted-by":"crossref","first-page":"291","DOI":"10.3109\/10428190109064585","article-title":"Telomere dynamics in myelodysplastic syndromes and acute leukemic transformation","volume":"42","author":"Ohyashiki","year":"2001","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.leukres.2010.05.023_bib50","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.leukres.2003.11.020","article-title":"Dynamics of telomere erosion and its association with genome instability in myelodysplastic syndromes (MDS) and acute myelogenous leukemia arising from MDS: a marker of disease prognosis?","volume":"28","author":"Sieglova","year":"2004","journal-title":"Leuk Res"},{"key":"10.1016\/j.leukres.2010.05.023_bib51","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/j.1365-2141.2004.05006.x","article-title":"Clonal haemopoiesis may occur after conventional chemotherapy and is associated with accelerated telomere shortening and defects in the NQO1 pathway; possible mechanisms leading to an increased risk of t-AML\/MDS","volume":"126","author":"Fern","year":"2004","journal-title":"Br J Haematol"},{"key":"10.1016\/j.leukres.2010.05.023_bib52","doi-asserted-by":"crossref","first-page":"579","DOI":"10.3109\/10428190009148406","article-title":"Telomerase activity in preleukemia and acute myelogenous leukemia","volume":"36","author":"Li","year":"2000","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.leukres.2010.05.023_bib53","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1016\/j.leukres.2005.03.006","article-title":"Telomerase activity in myelodysplastic syndromes","volume":"29","author":"Gurkan","year":"2005","journal-title":"Leuk Res"},{"key":"10.1016\/j.leukres.2010.05.023_bib54","first-page":"1475","article-title":"Telomerase activity in myelodysplastic syndrome","volume":"115","author":"Fu","year":"2002","journal-title":"Chin Med J"},{"key":"10.1016\/j.leukres.2010.05.023_bib55","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1182\/blood.V86.1.268.bloodjournal861268","article-title":"Apoptosis in bone marrow biopsy sample involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes","volume":"86","author":"Raza","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2010.05.023_bib56","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/S0145-2126(98)00051-4","article-title":"Bcl-2 expression by myeloid precursors in myelodysplastic syndromes: relation to disease progression","volume":"22","author":"Davis","year":"1998","journal-title":"Leuk Res"},{"key":"10.1016\/j.leukres.2010.05.023_bib57","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1080\/1042819031000083037","article-title":"Imbalance between apoptosis and telomerase activity in myelodysplastic syndromes: possible role in ineffective hemopoiesis","volume":"44","author":"Ohshima","year":"2003","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.leukres.2010.05.023_bib58","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1080\/10428190412331283251","article-title":"Survivin expression in acute leukemias and myelodysplastic syndromes","volume":"45","author":"Invernizi","year":"2004","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.leukres.2010.05.023_bib59","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/j.leukres.2004.03.020","article-title":"Expression of IAP family proteinsin myelodysplastic syndromes transforming to overt leukemia","volume":"28","author":"Yamamoto","year":"2004","journal-title":"Leuk Res"},{"key":"10.1016\/j.leukres.2010.05.023_bib60","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s00277-006-0215-0","article-title":"Survivin expression in \u201clow-risk\u201d and \u201chigh-risk\u201d myelodysplastic syndromes","volume":"86","author":"Gianelli","year":"2007","journal-title":"Ann Hematol"},{"key":"10.1016\/j.leukres.2010.05.023_bib61","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1016\/j.exphem.2009.09.002","article-title":"Accelerated cellular senescence in myelodysplastic syndrome","volume":"37","author":"Wang","year":"2009","journal-title":"Exp Hematol"},{"key":"10.1016\/j.leukres.2010.05.023_bib62","doi-asserted-by":"crossref","first-page":"2985","DOI":"10.1182\/blood.V91.8.2985.2985_2985_2990","article-title":"Methylation of p15 (INK4b) gene in myelodysplastic syndromes is frequent and acquired during disease progression","volume":"91","author":"Quesnel","year":"1998","journal-title":"Blood"},{"issue":"September","key":"10.1016\/j.leukres.2010.05.023_bib63","article-title":"p15INK4b methylation correlates with thrombocytopenia, blast percentage, and survival in myelodysplastic syndromes in a dose dependent manner: quantitation using pyrosequencing study","author":"Kim","year":"2009","journal-title":"Leuk Res"},{"key":"10.1016\/j.leukres.2010.05.023_bib64","doi-asserted-by":"crossref","first-page":"8482","DOI":"10.1158\/0008-5472.CAN-09-1153","article-title":"Progressive chromatin repression and promoter methylation of CTNNA1 associated with advanced myeloid malignancies","volume":"69","author":"Ye","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.leukres.2010.05.023_bib65","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1200\/JCO.2009.23.4781","article-title":"DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes","volume":"28","author":"Shen","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2010.05.023_bib66","doi-asserted-by":"crossref","first-page":"3285","DOI":"10.1182\/blood-2009-04-215814","article-title":"TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs)","volume":"114","author":"Kosmider","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2010.05.023_bib67","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/j.1365-2141.2009.07720.x","article-title":"Marked down regulation of the granulopoiesis regulator LEF1 is associated with disease progression in the myelodysplastic syndromes","volume":"146","author":"Pellagatti","year":"2009","journal-title":"Br J Haematol"},{"issue":"Suppl.","key":"10.1016\/j.leukres.2010.05.023_bib68","article-title":"Frequent mutations of the polycomb-associated gene ASXL1 in myelodysplastic syndromes and acute myeloid leukemia","volume":"114","author":"Boultwood","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2010.05.023_bib69","doi-asserted-by":"crossref","first-page":"4847","DOI":"10.1182\/blood-2009-08-236422","article-title":"Relationship of differential gene expression profiles in CD34+ myelodysplastic syndrome marrow cells to disease subtype and progression","volume":"114","author":"Sridhar","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2010.05.023_bib70","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1046\/j.0902-4441.2003.00190.x","article-title":"Erythropoietin has an anti-myeloma effect \u2013 a clinical observation supported by animal studies","volume":"72","author":"Mittelman","year":"2004","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.leukres.2010.05.023_bib71","doi-asserted-by":"crossref","first-page":"5181","DOI":"10.1073\/pnas.081275298","article-title":"Erythropoietin induces tumor regression and anti-tumor immune responses in murine myeloma models","volume":"98","author":"Mittelman","year":"2001","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.leukres.2010.05.023_bib72","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1111\/j.1365-2141.2006.06366.x","article-title":"Erythropoietin treatment in advanced multiple myeloma is associated with improved immunological functions: could it be beneficial in early disease?","volume":"135","author":"Prutchi-Sagiv","year":"2006","journal-title":"Br J Haematol"},{"issue":"756a","key":"10.1016\/j.leukres.2010.05.023_bib73","article-title":"T-cell abnormalities in patients with myelodysplastic syndromes: improved immunological functions in patients treated with recombinant erythropoietin","volume":"108","author":"Prutchi-Sagiv","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2010.05.023_bib74","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1200\/JCO.2001.19.11.2865","article-title":"Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial","volume":"19","author":"Littlewood","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2010.05.023_bib75","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1034\/j.1600-0609.2002.01530.x","article-title":"Serum erythropoietin (EPO) levels correlate with survival and independently predict response to EPO treatment in patients with myelodysplastic syndromes","volume":"68","author":"Wallvik","year":"2002","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.leukres.2010.05.023_bib76","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1182\/blood-2007-06-096370","article-title":"Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience","volume":"111","author":"Park","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2010.05.023_bib77","unstructured":"Rose C, Brechignac S, Vassilief D, et al. Positive impact of iron chelation therapy (CT) on survival in regularly transfused MDS patients. A prospective analysis by the GFM. Leuk Res in press [Blood 2007;110(Suppl.):80\u201381 (abstract)]."},{"key":"10.1016\/j.leukres.2010.05.023_bib78","doi-asserted-by":"crossref","first-page":"205","DOI":"10.3816\/CLK.2008.n.026","article-title":"Improved survival in patients with myelodysplastic syndrome receiving iron chelation therapy","volume":"2","author":"Leitch","year":"2008","journal-title":"Clin Leuk"},{"key":"10.1016\/j.leukres.2010.05.023_bib79","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1182\/blood-2008-03-143735","article-title":"WHO classification and WPSS predict post transplantation outcome in patients with myelodysplastic syndrome: a study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO)","volume":"112","author":"Alessandrino","year":"2008","journal-title":"Blood"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212610002821?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212610002821?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,6,6]],"date-time":"2020-06-06T02:03:03Z","timestamp":1591408983000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212610002821"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,12]]},"references-count":79,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2010,12]]}},"alternative-id":["S0145212610002821"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2010.05.023","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2010,12]]}}}